 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...2223242526272829303132...208209» |
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib combined with dalpiciclib in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_486;
P1
Pyrotinib combined with dalpiciclib showed acceptable safety profile and encouraging efficacy in refractory advanced HER2-positive GC, even for patients pretreated with anti-HER2 ADCs.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ?1: A post-hoc analysis of a phase III study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_480;
P3
In patients with HER2-negative GC/GEJA and PD-L1 CPS ?1, SHR-1701 in combination with CAPOX chemotherapy demonstrated clinically meaningful improvements in efficacy compared with placebo plus CAPOX, with a manageable safety profile. These findings are consistent with the results observed in the overall study population.
- AiRuiKa (camrelizumab) / HLB Bio Group
Efficacy and safety of camrelizumab plus gemcitabine and oxaliplatin as conversion therapy for unresectable gallbladder cancer: Interim results from a single-arm, phase II prospective clinical study (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_471;
P2
Camrelizumab combined with GEMOX shows promise as conversion therapy for unresectable GBC. However, further evaluation in a larger patient cohort is warranted.
- Cyclic kinase 4 and 6 inhibitor plus endocrine therapy (ET) as first-line therapies in advanced breast cancer: A patient-level data network meta-analysis (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_347;
In the first-line setting for HR+/HER2? advanced breast cancer, all CDK4/6 inhibitors combined with endocrine therapy significantly improve progression-free survival compared with endocrine therapy alone, with no significant differences observed among them.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
A multicenter real-world study on survival analysis of pyrotinib in HER2-positive metastatic breast cancer (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_298;
The updated analysis indicates that pyrotinib may serve as a promising therapeutic option for HER2-positive MBC with manageable toxicity in real-world settings. Survival outcomes remain under evaluation with extended follow-up.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pertuzumab versus pyrotinib in combination with trastuzumab and taxanes for first-line (1L) treatment of patients with HER2 (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_293;
Compared with the THP ,THPy significantly improved PFS in patients with untreated HER2+MBC. Notably, THPy demonstrated superior survival benefits specifically in subgroups with:premenopausal status, ECOG PS 0, de novo stage IV disease, previous untreated trastuzumab, Ki-67 ?20%, and liver metastases.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Efficacy and safety of mecapegfilgrastim for prophylaxis of dalpiciclib-induced neutropenia in patients with advanced HR+/HER2- breast cancer: A multicenter, open-label, randomized controlled phase II trial (Exhibition (Poster area)) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_291;
P2
Notably, THPy demonstrated superior survival benefits specifically in subgroups with:premenopausal status, ECOG PS 0, de novo stage IV disease, previous untreated trastuzumab, Ki-67 ?20%, and liver metastases. Mecapegfilgrastim reduced the incidence of grade ?3 dalpiciclib- induced neutropenia in the first cycle, thereby decreasing the rates of dalpiciclib interruption, dose reduction and discontinuation.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma (Hall 406) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_133;
P4
Adebrelimab plus SOX demonstrates superior pathological responses versus chemotherapy alone, establishing a promising neoadjuvant regimen for locally advanced gastric adenocarcinoma. Although associated with increased immune-related toxicity, the safety profile remains acceptable.
- plinabulin (BPI 2358) / BeyondSpring
Plinabulin/docetaxel vs. docetaxel in 2L/3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis (Hall 405) - Oct 3, 2025 - Abstract #ESMOAsia2025ESMO_Asia_32;
The durable survival benefit is supported by plinabulin's mechanism ofDC maturation and T cell activation. The positive benefit/risk ratio over docetaxel suggests a potential practice-changing treatment.
- | HHPG-19K (mecapegfilgrastim) / Jiangsu Hengrui Pharma
New P2 trial: ANC-IIT-004: Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy (clinicaltrials.gov) - Oct 3, 2025
P2, N=30, Recruiting, Sponsor: Affiliated Hospital of Nantong University
- plinabulin (BPI 2358) / BeyondSpring
Immune Activation with Plinabulin Promotes Monocyte-Macrophage Responses Combining Radiation with Immune Checkpoint Blockade (ICB) in ICB-Relapsed/Refractory Tumors (Poster Hall (Exhibit Halls AB); Virtual) - Oct 3, 2025 - Abstract #SITC2025SITC_993;
P1/2
There was no baseline difference in TIIC-associated GEF-H1 immune scores between PR+SD and PD groups, whereas total MoMac-associated GEF-H1 immune score was higher in PD group when compared to PR+SD group. Further subgroup analysis of MoMac I-IV suggests that AGR1+ MoMac-III may represent the dominating pro-tumor M2 phenotype and that plinabulin combined with RT+ICB drives differential monocyte-macrophage responses in responders.Conclusions In addition to maturation of DCs to generate a systemic immune response, plinabulin combined with radiation and ICB promotes proinflammatory monocytes and M1 polarization via a GEF-H1-dependent mechanism with the potential of overcoming acquired ICB resistance from pro-tumor macrophages.Ethics Approval Among the 19 patients evaluable for safety, 1 male (Hispanic or Latino) patient entered 'other' ethnics and should be added to the 18 patients under 'Racial Categories'.
- | cyclosporin A microemulsion / Generic mfg., Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Retrospective data, Journal: Adding recombinant human thrombopoietin to cyclosporine A and hetrombopag enhances the early hematologic response in transfusion-dependent non-severe aplastic anemia: a retrospective study. (Pubmed Central) - Oct 3, 2025
Adverse events were comparable between groups. Adding rhTPO to CsA?+?hetrombopag improves platelet recovery and early hematologic responses, supporting its potential role in optimizing the initial management of patients with TD-NSAA.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Checkpoint inhibition: Overlapping Syndrome of Myocarditis, Myositis, Transaminitis, and Myasthenia Gravis in a Patient with Hepatocellular Carcinoma after Treatment with Immune Checkpoint Inhibitors: A Case Report and Literature Review. (Pubmed Central) - Oct 3, 2025
IrAEs are common after ICI treatment. After ICI treatment initiation, close monitoring, early detection, and treatment of irAEs is required to improve clinical outcomes.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (clinicaltrials.gov) - Oct 3, 2025
P2, N=184, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||||||| HR091506 / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults (clinicaltrials.gov) - Oct 2, 2025
P3, N=765, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
After ICI treatment initiation, close monitoring, early detection, and treatment of irAEs is required to improve clinical outcomes. Not yet recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Aug 2025
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma (clinicaltrials.gov) - Oct 2, 2025
P2, N=30, Recruiting, Sponsor: Peking University Cancer Hospital & Institute
Not yet recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Aug 2025 Not yet recruiting --> Recruiting
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Clinical, P1 data, PK/PD data, Journal: Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers. (Pubmed Central) - Oct 2, 2025
In healthy Chinese male volunteers, the bioavailability of the SHR0302 oral solution was comparable to that of the SHR0302 tablet. The drug was safe and well tolerated following a single dose.
- | Review, Journal: IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions. (Pubmed Central) - Oct 2, 2025
P1
The use of IDO/TDO inhibitors with conventional anticancer medications demonstrates their potential to reshape cancer treatment paradigms, contingent on further research to optimize efficacy and safety. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT03844438.
- | Clinical, Retrospective data, Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Efficacy and safety of immune checkpoint inhibitors for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis. (Pubmed Central) - Oct 2, 2025
For PD-L1?50% tumors, penpulimab showed excellent OS and PFS; for PD-L1 1-49% tumors, pembrolizumab+chemo and camrelizumab+chemo achieved the best OS and PFS, respectively; for PD-L1?1% tumors, the tislelizumab+chemo and camrelizumab+chemo showed the best OS and PFS results, while for tumors with PD-L1 <1%, both nivolumab and serplulimab+chemo provided significant survival benefit...Ipilimumab+chemo had the highest incidence of adverse events (AEs) [OR = 2.0, 95% CI:(1.5-2.7)]. https://www.crd.york.ac.uk/prospero/, identifier CRD420251027447.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal, Intubation: Comparison of remimazolam tosylate and sevoflurane for anesthesia induction with preserved spontaneous respiration during tracheal intubation: a prospective, single-center, randomized controlled trial. (Pubmed Central) - Oct 2, 2025
https://www.crd.york.ac.uk/prospero/, identifier CRD420251027447. Compared with sevoflurane, remimazolam can be safely and effectively used for intubation while preserving spontaneous breathing, with a shorter time to achieve conditions for topical anesthesia and intubation.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Case Report: Apatinib combined with IMRT concurrent therapy achieves rapid response and significantly prolongs progression-free survival in elderly patients with inoperable locally advanced esophageal squamous cell carcinoma. (Pubmed Central) - Oct 1, 2025
As of July 2024, the patient has achieved a progression-free survival of 71 months without experiencing severe (Grade III/IV) adverse reactions. Therefore, apatinib combined with radiotherapy suggests potential benefits as a concurrent treatment option for elderly patients with unresectable LA-ESCC.
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC (clinicaltrials.gov) - Sep 30, 2025
P2, N=30, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- ||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment change, Platinum sensitive: A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Sep 30, 2025
P1/2, N=150, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Therefore, apatinib combined with radiotherapy suggests potential benefits as a concurrent treatment option for elderly patients with unresectable LA-ESCC. N=50 --> 150
- |||||||||| Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P3 trial: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer (clinicaltrials.gov) - Sep 29, 2025
P3, N=650, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Retrospective data, Journal: Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study. (Pubmed Central) - Sep 29, 2025
This study aimed to evaluate the efficacy and safety of vascular-targeting agents apatinib or anlotinib plus chemotherapy for RM-NPC treatment.MethodsThis retrospective multicenter study, conducted at 4 hospitals in Guangxi Province, China, between January 2017 and December 2021, included 198 patients. The combination group exhibited a higher median OS compared to the chemotherapy alone group (45
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Clinical, P3 data, Retrospective data, Journal: Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III, randomized controlled trial. (Pubmed Central) - Sep 29, 2025
P3
The incidence of adverse events was 80.5%, 90.1%, and 90.1% in the North, Central, and South China groups, respectively. The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis.
- | AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Journal: Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review. (Pubmed Central) - Sep 29, 2025
Emerging evidence indicates that elevated IL-17 levels modulate keratinocyte proliferation and immune cell infiltration, contributing to ACH pathogenesis and representing a promising therapeutic target. Herein, we presented a case of ACH successfully treated with vunakizumab, China's first self-developed anti-IL-17A monoclonal antibody, and reviewed publications reporting IL-17 targeted therapies for ACH, highlighting the potential benefit of IL-17 targeted therapy in ACH management.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker: Long-term complete remission with immunotherapy in advanced RET fusion-positive NSCLC with brain metastases: a case report and literature review. (Pubmed Central) - Sep 29, 2025
NSCLC patients who have PD-L1 overexpression and RET fusion-positivity may respond well to immunotherapy. Combining radiotherapy with immunotherapy may enhance local control of brain metastases.
- | otesaconazole (VT-1161) / Mycovia Pharma
Journal: Azole resistance: insights from Y132 substitutions in Candida sterol 14?-demethylase utilizing molecular dynamics simulations. (Pubmed Central) - Sep 29, 2025
Far higher binding free energy of fluconazole in comparison with VT1 might partly explain its susceptibility to azole-resistant substitutions. The results give key insights into azole resistance, and antifungal drug discovery and optimization.
- | Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 25, 2025
P2, N=41, Not yet recruiting, Sponsor: West China Hospital
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Clinical, P3 data, Retrospective data, Journal: Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a post hoc analysis of a phase-III trial. (Pubmed Central) - Sep 25, 2025
P3
The nomogram demonstrated good calibration performance (mean absolute error: 0.021) with a limited discriminative ability (C-index: 0.580). Early response rate to vunakizumab was 54.0% in patients with moderate-to-severe plaque psoriasis, where female gender and na
- | leucovorin calcium / Generic mfg., AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker: Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review. (Pubmed Central) - Sep 25, 2025
Despite showing improved efficacy and a more favorable safety profile compared to olaparib in preclinical studies, clinical evidence for its application in pancreatic adenocarcinoma harboring gBRCAm remains limited...This case underscores the important role of biomarker-directed therapy in pancreatic adenocarcinoma and fuzuloparib may represent a potential PARP inhibitor option for maintenance treatment in pancreatic adenocarcinoma with gBRCAm. However, large-scale randomized controlled trials are needed to validate these results.
- | colchicine / Generic mfg., plinabulin (BPI 2358) / BeyondSpring
Review, Journal: Dynamic Microtubules as Sensors in Animal Cells. (Pubmed Central) - Sep 25, 2025
In tissue cells with stable morphologies, the sensory functions of microtubules may be as or more important than their architectural functions. This re-framing of microtubule biology suggests new directions for mechanistic inquiry and drug discovery.
- | New P1/2 trial, IO biomarker: Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (clinicaltrials.gov) - Sep 24, 2025
P1/2, N=246, Not yet recruiting, Sponsor: First Affiliated Hospital of Wenzhou Medical University
- |||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
Enrollment closed, Trial primary completion date: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Sep 24, 2025
P3, N=55, Active, not recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
This re-framing of microtubule biology suggests new directions for mechanistic inquiry and drug discovery. Recruiting --> Active, not recruiting | Trial primary completion date: May 2025 --> Aug 2025
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1/2 trial: Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy (clinicaltrials.gov) - Sep 24, 2025
P1/2, N=33, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
- | Journal: Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry (Pubmed Central) - Sep 24, 2025
sensitivity and simplicity? making it a powerful tool for rapid risk screening and simultaneous quantitative analysis of JAK inhibitors in anti-alopecia cosmetics.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, letrozole / Generic mfg.
Journal: Case Report: Synchronous cervical, gastric and rectal metastases in occult breast cancer. (Pubmed Central) - Sep 24, 2025
Following six months of treatment with letrozole (1mg/day) in combination with dalpiciclib the patient demonstrated significant symptomatic relief, with remarkable reduction in the lesions located in the cervix, stomach, and rectum. This case represents the first documented instance of occult primary breast cancer with simultaneous metastases to the cervix, stomach, and rectum.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). (Pubmed Central) - Sep 24, 2025
The combination of Eribulin and Pyrotinib emerges as a viable treatment option for HER2-positive advanced breast cancer patients who have exhibited resistance to trastuzumab. Despite advancements in anti-HER2 therapies, further research is required to address remaining challenges in this specific clinical scenario.
- | AiRuiKa (camrelizumab) / Elevar Therapeutics, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. (clinicaltrials.gov) - Sep 23, 2025
P3, N=48, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Despite advancements in anti-HER2 therapies, further research is required to address remaining challenges in this specific clinical scenario. N=560 --> 48 | Trial completion date: Oct 2023 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Aug 2025; Terminated by Sponsor
- ||| HR19042 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. (clinicaltrials.gov) - Sep 23, 2025
P2, N=316, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=560 --> 48 | Trial completion date: Oct 2023 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Aug 2025; Terminated by Sponsor Recruiting --> Active, not recruiting | N=210 --> 316 | Trial completion date: May 2024 --> Nov 2025 | Trial primary completion date: Feb 2024 --> Nov 2025
- || AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
PK/PD data, Journal: Safety, pharmacokinetics, and bioequivalence of vunakizumab injection, a specific dermatitis drug, in healthy Chinese volunteers: an open-label, randomized, two-stage, two-sequence cross-over study. (Pubmed Central) - Sep 23, 2025
P1
Both injection devices were well-tolerated in terms of safety. Participants preferred a single 2?mL subcutaneous injection over two 1?mL subcutaneous injections.Clinical Trial Registration www.clinicaltrials.gov, identifier: NCT06182384.
- | plinabulin (BPI 2358) / BeyondSpring
Journal: Design, synthesis, and structure-activity relationship study of novel plinabulin derivatives as anti-tumor agents based on the co-crystal structure. (Pubmed Central) - Sep 22, 2025
The compounds 16c (IC50?=?2.0, NCI-H460; IC50?=?1.2 nM, BxPC-3; IC50?=?1.97 nM, HT-29) and 26r (IC50?=?0.96, NCI-H460; IC50?=?0.66 nM, BxPC-3; IC50?=?0.61 nM, HT-29) had the best activity. The cytotoxic activity of compound 26r against various tumor cell lines occurred at less than 1
- ||| Enrollment open: A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov) - Sep 22, 2025
P2, N=200, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
The cytotoxic activity of compound 26r against various tumor cell lines occurred at less than 1 Not yet recruiting --> Recruiting
- ||| HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open: A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2025
P1/2, N=118, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Predicting Postoperative Pneumonia in ESCC After Neoadjuvant Chemo-Immunotherapy: Combined Use of ARISCAT Score and Inflammatory Biomarkers. (Pubmed Central) - Sep 22, 2025
We retrospectively analyzed 312 patients with resectable ESCC who underwent two cycles of platinum-based chemotherapy plus camrelizumab followed by McKeown esophagectomy between 2018 and 2023...Integrating ARISCAT with inflammatory biomarkers enhances predictive performance, enabling refined preoperative risk stratification and potentially guiding targeted preventive strategies. Prospective multicenter validation is warranted.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Journal, BRCA Biomarker, PARP Biomarker: Case Report: Multimodal management of a rare pediatric astroblastoma using proton beam therapy and Gamma Knife radiosurgery-a case report and literature review. (Pubmed Central) - Sep 22, 2025
Following the discovery of a BRCA2 mutation, the PARP inhibitor fluzoparib was administered, which was associated with temporary disease stabilization...This case suggests that leveraging the tissue-sparing benefits of initial PBT may enable effective salvage SRS for managing residual or recurrent high-grade pediatric astroblastoma. Furthermore, it highlights the potential role of molecular profiling to guide targeted therapies in these rare tumors.
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Journal, Real-world evidence: Real-world Efficacy and Safety of Flumatinib as the First-line Treatment in Patients With de novo Philadelphia-positive Acute Lymphoblastic Leukemia. (Pubmed Central) - Sep 21, 2025
T315I and Y253H mutations were key drivers of relapse. Although allo-HSCT enhanced survival, longer follow-up period and prospective trials are warranted to validate these findings.
- |||||||||| ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
New P3 trial: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov) - Sep 19, 2025
P3, N=576, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- ||| HRS-4642 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov) - Sep 19, 2025
P1/2, N=47, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Although allo-HSCT enhanced survival, longer follow-up period and prospective trials are warranted to validate these findings. Enrolling by invitation --> Active, not recruiting | N=70 --> 47